The iPSC-derived NK cells pipeline includes 12+ active players and 15+ drugs in development. FT522 is in Phase I, while CNTY-101 and NCR300 are among other programs in the clinic.
The myelofibrosis therapeutic pipeline now includes over 40 candidates from more than 35 companies, with recent developments including Orphan Drug Designation for CK0804 and multiple Phase III trial initiations. Key clinical milestones include completed enrollment in Karyopharm's SENTRY trial and upcoming Phase I data from Incyte's combination therapy studies.
The FDA is set to make decisions on four drug applications in April 2026, including Orca-T for hematological malignancies, orforglipron for obesity, sparsentan for kidney disease, and a doravirine/islatravir combination for HIV-1.
Faron Pharmaceuticals announces acceptance of bexmarilimab Phase I/II data for poster presentation at BSH 2026, while launching a new Phase II BEAM-X study evaluating the drug in AML patients post-stem cell transplantation.
ExCellThera's cell therapy Zemcelpro (dorocubicel) has been granted NUB Status 1 in Germany, allowing hospitals to apply for temporary supplementary reimbursement. 220 German hospitals have expressed interest in offering the therapy in 2026.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07591168 |
A Study of BL-M11D1 in Patients With Relapsed/Refractory Myelodysplastic Syndromes |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07578675 |
Brain Cognitive Network Abnormalities in Anemia Patients Using fNIRS |
RECRUITING | |
| NCT07572929 |
A Pragmatic Clinical Trial to Prevent Relapse for Myeloid Malignancies With Measurable Disease Prior to Allogeneic Transplant |
NOT_YET_RECRUITING | PHASE2 |
| NCT07570056 |
Use of Electrical Bioimpedance in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Patients (Bioimpedance) |
NOT_YET_RECRUITING | |
| NCT07566377 |
Cord Blood Transplantation in Children and Young Adults With Blood Cancer |
RECRUITING | PHASE2 |
| NCT07493538 |
MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases |
RECRUITING | PHASE2 |
| NCT07469592 |
eHealth Mindfulness-based Music Therapy Intervention for Patients Undergoing Stem Cell Transplantation |
NOT_YET_RECRUITING | NA |
| NCT07449286 |
IFN-α in Relapse Prevention. |
NOT_YET_RECRUITING | PHASE2 |
| NCT07387354 |
Pacritinib With Aza for Upfront Myelodysplastic Syndrome |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07319845 |
A Study of TAK-226 for Transfusion-Dependent Anemia in Japanese Patients With Lower-Risk Myelodysplastic Syndromes |
NOT_YET_RECRUITING | PHASE2 |
